Annexon biosciences to participate in upcoming may investor conferences

Brisbane, calif., may 05, 2022 (globe newswire) -- annexon, inc. (nasdaq: annx), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that douglas love, esq., president & chief executive officer, will participate in fireside chats during the following may investor conferences:
ANNX Ratings Summary
ANNX Quant Ranking